Trial Profile
Phase I/II Trial of MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer: A Study by the Stem Cell Clinical Consortium
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; MK 0752 (Primary) ; Pegfilgrastim
- Indications Advanced breast cancer
- Focus Adverse reactions
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual initiation date changed from Feb 2008 to Mar 2008 as reported by ClinicalTrials.gov.
- 18 Jun 2012 Planned End Date changed from 1 Mar 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov record.